683 related articles for article (PubMed ID: 32519423)
41. Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa/Bim/Mcl-1/p-Chk1 axis.
Zhang J; Wang Y; Yin C; Gong P; Zhang Z; Zhao L; Waxman S; Jing Y
Cell Death Dis; 2022 Apr; 13(4):379. PubMed ID: 35443722
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
[TBL] [Abstract][Full Text] [Related]
43. Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells.
Carter BZ; Mak PY; Tao W; Zhang Q; Ruvolo V; Kuruvilla VM; Wang X; Mak DH; Battula VL; Konopleva M; Jabbour EJ; Hughes PE; Chen X; Morrow PK; Andreeff M
Mol Cancer Ther; 2022 Jun; 21(6):879-889. PubMed ID: 35364607
[TBL] [Abstract][Full Text] [Related]
44. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
45. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
[TBL] [Abstract][Full Text] [Related]
46. Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond.
Choi JH; Bogenberger JM; Tibes R
Target Oncol; 2020 Apr; 15(2):147-162. PubMed ID: 32319019
[TBL] [Abstract][Full Text] [Related]
47. Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist Venetoclax.
Satta T; Li L; Chalasani SL; Hu X; Nkwocha J; Sharma K; Kmieciak M; Rahmani M; Zhou L; Grant S
Clin Cancer Res; 2023 Apr; 29(7):1332-1343. PubMed ID: 36652560
[TBL] [Abstract][Full Text] [Related]
48. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
49. Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.
Thijssen R; Diepstraten ST; Moujalled D; Chew E; Flensburg C; Shi MX; Dengler MA; Litalien V; MacRaild S; Chen M; Anstee NS; Reljić B; Gabriel SS; Djajawi TM; Riffkin CD; Aubrey BJ; Chang C; Tai L; Xu Z; Morley T; Pomilio G; Bruedigam C; Kallies A; Stroud DA; Bajel A; Kluck RM; Lane SW; Schoumacher M; Banquet S; Majewski IJ; Strasser A; Roberts AW; Huang DCS; Brown FC; Kelly GL; Wei AH
Blood; 2021 May; 137(20):2721-2735. PubMed ID: 33824975
[TBL] [Abstract][Full Text] [Related]
50. Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia.
Zhang L; Cai T; Lin X; Huang X; Bui MH; Plotnik JP; Bellin RJ; Faivre EJ; Kuruvilla VM; Lam LT; Lu X; Zha Z; Feng W; Hessler P; Uziel T; Zhang Q; Cavazos A; Han L; Ferguson DC; Mehta G; Shanmugavelandy SS; Magoc TJ; Rowe J; Goodwin NC; Dorritie KA; Boyiadzis M; Albert DH; McDaniel KF; Kati WM; Konopleva M; Shen Y
Mol Cancer Ther; 2021 Oct; 20(10):1809-1819. PubMed ID: 34253595
[TBL] [Abstract][Full Text] [Related]
51. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
[TBL] [Abstract][Full Text] [Related]
52. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM
Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331
[TBL] [Abstract][Full Text] [Related]
53. Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Richter A; Fischer E; Holz C; Schulze J; Lange S; Sekora A; Knuebel G; Henze L; Roolf C; Murua Escobar H; Junghanss C
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803402
[TBL] [Abstract][Full Text] [Related]
54. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
55. Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate.
Kawakatsu R; Tadagaki K; Yamasaki K; Yoshida T
Sci Rep; 2024 Feb; 14(1):4975. PubMed ID: 38424468
[TBL] [Abstract][Full Text] [Related]
56. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
58. Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway.
Wu HY; Li KX; Pan WY; Guo MQ; Qiu DZ; He YJ; Li YH; Huang YX
Int Immunopharmacol; 2022 Mar; 104():108497. PubMed ID: 34999394
[TBL] [Abstract][Full Text] [Related]
59. Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress-CHOP pathway.
Hua L; Yang N; Li Y; Huang K; Jiang X; Liu F; Yu Z; Chen J; Lai J; Du J; Zeng H
Br J Haematol; 2023 Sep; 202(5):971-984. PubMed ID: 37409755
[TBL] [Abstract][Full Text] [Related]
60. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.
Singh Mali R; Zhang Q; DeFilippis RA; Cavazos A; Kuruvilla VM; Raman J; Mody V; Choo EF; Dail M; Shah NP; Konopleva M; Sampath D; Lasater EA
Haematologica; 2021 Apr; 106(4):1034-1046. PubMed ID: 32414851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
